Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALLO Stock Price Chart Interactive Chart >
ALLO Price/Volume Stats
|Current price||$26.10||52-week high||$46.85|
|Prev. close||$25.76||52-week low||$23.30|
|Day high||$26.12||Avg. volume||1,057,386|
|50-day MA||$29.48||Dividend yield||N/A|
|200-day MA||$32.49||Market Cap||3.69B|
Allogene Therapeutics, Inc. (ALLO) Company Bio
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.
ALLO Latest News Stream
|Loading, please wait...|
ALLO Latest Social Stream
View Full ALLO Social Stream
Latest ALLO News From Around the Web
Below are the latest news stories about Allogene Therapeutics Inc that investors may wish to consider to help them evaluate ALLO as an investment opportunity.
We all want to build a profitable portfolio – but if you’re new to the markets, and starting from scratch, where do you begin? It’s tempting to buy into the big names, the companies that have been making waves and generating headlines. Tempting, but probably not the best idea. These companies have already made their splash; while they will continue to bring returns, they might not be the best choice for a retail investors looking to expand a return-oriented portfolio. Start by looking low. Not at down-and-out stocks, but at fundamentally sound equities that are trading at recent low prices.
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL StudiesResults from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrated Six Month Complete Response (CR) Rate of 36% in CAR T Naïve LBCL Patients Treated with ALLO-501 Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL)Overall Response Rate (ORR) of 75
Allogene said its donor cell-derived cancer treatment was successful for six months. Could it take on Gilead and Novartis?
Dozens of companies released data in advance of the American Society of Clinical Oncology gathering, which begins June 4.
ALLO Price Returns